H18 * Tivantinib in combination with Carboplatin and Pemetrexed as first line treatment in patients with advanced non-squamous NSCLC or Malignant Pleural Mesothelioma: results of phase I trial

(Source: Annals of Oncology)

from MedWorm: Mesothelioma http://ift.tt/1MrmYep